Metformin improves insulin resistance and Glimepiride stimulates insulin secretion. It has superior efficacy to monotherapy in type 2 diabetes patients and prevents microvascular complications of diabetes. It decreases hepatic glucose production and is superior in the management of metabolic variables, especially insulin resistance and beta-cell secretion capacity. It is given to patients with symptoms related to Type 2 diabetes mellitus and hyperinsulinemia.
Glimepiride + Metformin is a combination of two antidiabetic medicines: Glimepiride and Metformin. Glimepiride is a sulfonylurea which works by increasing the amount of insulin released by the pancreas in order to lower blood glucose. Metformin is a biguanide which works by lowering glucose production in the liver, delaying glucose absorption from the intestines, and increasing the body’s sensitivity to insulin.